- Home
- RLMD vs SOR Comparison
RLMD vs SOR Comparison
Compare RLMD & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLMD | SOR |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.9M | 383.4M |
| IPO Year | 2012 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RLMD | SOR |
|---|---|---|
| Price | $4.07 | $45.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.40 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 10.7K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $1.47 | $44.20 |
| 52 Week High | $8.00 | $50.41 |
Technical Indicators
Market Signals| Indicator | RLMD | SOR |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 40.66 |
| Support Level | $3.99 | $45.09 |
| Resistance Level | $4.51 | $46.77 |
| Average True Range (ATR) | 0.21 | 0.75 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 12.31 | 17.65 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.